Deals in Depth: January 2011
Executive Summary
Eli Lilly and Boehringer Ingelheim signed a risk-sharing deal worth over $2 billion to co-develop several diabetes candidates. To gain access to viral cancer vaccines, Amgen paid $425 million up front for BioVex, which could get another $575 million in regulatory and sales earn-outs. Three fundraises (from Symphogen, Nektar, and Pharmasset) that brought in over $100 million each contributed significantly to the $1.1 billion in biopharma financing. For the first time in six months, no device company completed a public offering in January - money invested in this industry totaled only $188 million, a 52% decrease from December's $391 million.
You may also be interested in...
US High Court Punts On ‘Objective Falsity’ FCA Standard
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
EU Launches ‘Structured Dialog’ To Thrash Out Supply Chain Concerns
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
Samsung Bioepis Pushes Stelara Rival Into Phase I
Samsung Bioepis has announced that its SB17 proposed biosimilar ustekinumab rival to Janssen’s $7.7bn Stelara brand has moved into Phase I trials.
Need a specific report? 1000+ reports available
Buy Reports